253 related articles for article (PubMed ID: 23314623)
1. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis.
Sakai T; Watanabe H; Kuroyanagi K; Akiyama G; Okano K; Kohno H; Tsuneoka H
Br J Ophthalmol; 2013 Mar; 97(3):338-42. PubMed ID: 23314623
[TBL] [Abstract][Full Text] [Related]
2. Vision- and health-related quality of life in patients with Behçet uveitis.
Onal S; Savar F; Akman M; Kazokoglu H
Arch Ophthalmol; 2010 Oct; 128(10):1265-71. PubMed ID: 20937995
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
4. Quality of life after macular translocation with 360 degrees peripheral retinectomy for age-related macular degeneration.
Cahill MT; Stinnett SS; Banks AD; Freedman SF; Toth CA
Ophthalmology; 2005 Jan; 112(1):144-51. PubMed ID: 15629835
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.
Markomichelakis N; Delicha E; Masselos S; Sfikakis PP
Am J Ophthalmol; 2012 Sep; 154(3):534-541.e1. PubMed ID: 22789563
[TBL] [Abstract][Full Text] [Related]
6. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.
Yamada Y; Sugita S; Tanaka H; Kamoi K; Kawaguchi T; Mochizuki M
Br J Ophthalmol; 2010 Mar; 94(3):284-8. PubMed ID: 19692382
[TBL] [Abstract][Full Text] [Related]
7. Effect of laser photocoagulation treatment for diabetic macular oedema on patient's vision-related quality of life.
Tranos PG; Topouzis F; Stangos NT; Dimitrakos S; Economidis P; Harris M; Coleman AL
Curr Eye Res; 2004 Jul; 29(1):41-9. PubMed ID: 15370366
[TBL] [Abstract][Full Text] [Related]
8. Effect of vitrectomy for epiretinal membrane on visual function and vision-related quality of life.
Okamoto F; Okamoto Y; Hiraoka T; Oshika T
Am J Ophthalmol; 2009 May; 147(5):869-74, 874.e1. PubMed ID: 19200531
[TBL] [Abstract][Full Text] [Related]
9. Normative comparison of patient-reported outcomes in patients with noninfectious uveitis.
Naik RK; Rentz AM; Foster CS; Lightman S; Belfort R; Lowder C; Whitcup SM; Kowalski JW; Revicki DA
JAMA Ophthalmol; 2013 Feb; 131(2):219-25. PubMed ID: 23411886
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
11. Quality of Life in Patients with Noninfectious Uveitis Treated with or without Systemic Anti-inflammatory Therapy.
Gui W; Dombrow M; Marcus I; Stowe MH; Tessier-Sherman B; Yang E; Huang JJ
Ocul Immunol Inflamm; 2015 Apr; 23(2):135-43. PubMed ID: 24867459
[TBL] [Abstract][Full Text] [Related]
12. Responsiveness of Vision-Specific and General Quality of Life Metrics to Ocular and Systemic Events in Patients with Uveitis.
Sugar EA; Burke AE; Venugopal V; Thorne JE; Holbrook JT;
Ophthalmology; 2020 Dec; 127(12):1710-1718. PubMed ID: 32717341
[TBL] [Abstract][Full Text] [Related]
13. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
Tabbara KF; Al-Hemidan AI
Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
15. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
16. Vision-related quality of life in patients with bilateral severe age-related macular degeneration.
Cahill MT; Banks AD; Stinnett SS; Toth CA
Ophthalmology; 2005 Jan; 112(1):152-8. PubMed ID: 15629836
[TBL] [Abstract][Full Text] [Related]
17. Vision- and health-related quality of life in patients with visual field loss after postchiasmatic lesions.
Gall C; Lucklum J; Sabel BA; Franke GH
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2765-76. PubMed ID: 19117930
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with adalimumab in the treatment of ocular Behçet disease.
Bawazeer A; Raffa LH; Nizamuddin SH
Ocul Immunol Inflamm; 2010 Jun; 18(3):226-32. PubMed ID: 20482404
[TBL] [Abstract][Full Text] [Related]
19. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.
Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238
[TBL] [Abstract][Full Text] [Related]
20. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease.
Okada AA; Goto H; Ohno S; Mochizuki M;
Arch Ophthalmol; 2012 May; 130(5):592-8. PubMed ID: 22652845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
